Aptinyx Inc. is planning an IPO on the Nasdaq global market.
The Evanston, Ill.-based company, which plans to list its common stock under the APTX symbol, is looking to raise up to $80 million which will be used for clinical trials, working capital and other general corporate purposes.
J.P. Morgan Securities LLC, Cowen and Co. LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the IPO and as representatives of the underwriters.
Aptinyx develops therapies for brain and nervous system disorders.
